Our Company

ExThera Medical develops and commercializes extracorporeal blood filtration devices, including the Seraph^® 100 Microbind^® Affinity Blood Filter, and ONCOBind™ Blood Filter for removing a broad range of harmful substances from the bloodstream of patients. ExThera Medical’s extracorporeal products have demonstrated life-saving capabilities in a wide range of critically ill patients suffering from severe infections, and the potential to treat stage 4 metastatic cancer patients. With a growing body of outcome and health economic evidence from independent clinical studies, participation in the DARPA dialysis-like therapeutics program, from successful clinical use in the U.S. and EU for the treatment of bloodstream infections, and with positive in vitro test results demonstrating removal of circulating tumor cells, the company is well-positioned to serve healthcare professionals and patients alike.

ExThera Medical was formed in 2007 through a joint venture between the Emergence Venture Partners Life Science Incubator and ExThera AB at the Karolinska Institute of Stockholm with a focus on therapeutic applications to address antimicrobial resistance (AMR). From this collaboration, the application of novel pathogen and circulating tumor cell adsorption intellectual property was developed to what is now branded as the Seraph^® 100 and ONCOBind™ blood filters.

Robert Ward, NAE, Ph.D. (h) | Chairman and President

Prior to ExThera, Robert Ward was President, CEO, and Founder of the Polymer Technology Group (PTG) in Berkeley, California. PTG was sold to Royal DSM with a 132X investor return. Prior to a successful entrepreneurial career, Robert was Director of Research at Avco Medical Products and later spent a decade at Thoratec as President of the Biomaterials Division. He has numerous technical publications and patents and has received multiple awards and recognitions. Robert studied engineering management and polymer science at Northeastern University and received a bachelor’s degree in chemical engineering from the University of Massachusetts, Lowell.

Keith McCrea, Ph.D. | Vice President of Research and Development and Chief Science Officer

Keith McCrea began his career at The Polymer Technology Group (PTG), where he built a state-of-the-art surface analysis laboratory focusing on a custom-built advanced laser technique that has been used to aid in the identification and development of new intellectual property at ExThera. Keith has led R&D projects to develop new materials for several different medical applications and has a doctorate in physical chemistry, with an emphasis on surface modification and characterization from University of California, Berkeley. Keith also serves on the scientific advisory board of NESAC/BIO, an NIH-sponsored program at the University of Washington with a mission to develop new techniques to solve biomedical related problems associated with surfaces and interfaces.

Erin Borger | Chief Executive Officer

Prior to joining ExThera, Erin spent 20 years in finance at both Morgan Stanley and UBS Financial Services. Erin has extensive board experience in healthcare and education. He currently sits on the Boards of Sepsis Alliance and the Applebaum Foundation. Previously he held positions as Board Member or equivalent for Longeveron (NASD:LGVN), National Parkinson’s Foundation, University of Miami Miller School of Medicine, Chris Evert Children’s Hospital Foundation, Queen for a Day Foundation, Crockett Foundation, Palisades Medical Center Foundation, F.I.N. Sea Foundation, Avon Old Farm School, and many others.

Sallie Coviello | Chief Operating Officer and Vice President of Quality

Sallie began her career in research and development at The Polymer Technology Group (PTG) working directly with physicians and engineers to develop and fabricate medical device prototypes used in benchtop and clinical studies. Since then, she has gained 25+ years of experience in a variety of positions including Principle Quality Engineer, Director of Device Development, Director of Manufacturing at DSM Biomedical and VP of Operations at Actamax Surgical Materials, LLC, then a DSM Biomedical-DuPont joint venture. Sallie’s background in Class II and III devices allowed her to experience quality from a variety of perspectives and provided an ideal basis for her transition to quality management in the medical device industry. Sallie received a Bachelor of Science in Industrial Technology, Product Design with a minor in Business Administration from San Francisco State University.

Michael DiMeo, M.B.A. | Chief Financial Officer

Michael DiMeo, the company’s Chief Financial Officer, leverages over 25 years of experience in financial management and capital structuring of MedTech companies in life science, oncolytic and exosome diagnostics. As Chief Financial Officer for Vibalogics, Michael led M&A activities to accelerate the company’s successful sale in just one year. Michael was part of the integration team for the landmark merger of Thermo Electron and Fisher Scientific and went on to serve in finance leadership roles to transform the profitability of multiple Thermo Fisher Scientific businesses. He was the finance lead for Eastman Kodak’s photographic gelatin business. Michael has an undergraduate degree in Biology and an MBA from Northeastern University in Boston.

Sanja Ilic, M.D., M.S., RAC | Chief Regulatory Officer and Vice President of Clinical, Regulatory and Medical Affairs

Dr. Sanja Ilic, the company’s Chief Regulatory Officer, is an internationally recognized Physician with over 25 years of global regulatory, clinical, and medical affairs experience in the healthcare industry (Johnson & Johnson, Medtronic, Hologic, and startups), with demonstrated ability to establish successful clinical development and medical affairs strategies, and efficiently secure regulatory approvals in many categories of medical systems including diagnostics, Class I, II and Class III devices, and Device Drug/Biologic combination products. Extensive track record in guiding excellence in product safety and development, focusing on achieving successful global product launches, developing strong relationships with regulatory authorities, building deep technical knowledge and talent bases, and implementing strategic process improvements.

Samuel  Shull, M.B.A. | Chief Commercial Officer

Sam has served in several global commercial leadership roles with more than 20 years’ experience in the hospital sector. For the last 10 years he has served the renal extracorporeal critical care community commercializing medical devices, pharmaceuticals, and in vitro diagnostic products. Career highlights include product marketing through notable acquisitions; Most recently Astute Medical and subsequent acquisition, and Gambro/Baxter International/Inc. Experience includes responsibility for product launches, early market development commercial growth, >$100M mature product portfolio management, and strategic development initiatives therein. Sam has a Master’s of Business Administration degree in Finance and International Management from the UC Davis Graduate School of Management and a Bachelor’s degree in Mechanical Engineering from the UC Davis College of Engineering.

Dr. Lakhmir Chawla, M.D.

Prior to joining the board, Dr. Chawla was a professor of medicine at the George Washington University Medical Center in Washington, D.C. where he directed research efforts for the Division of Critical Care Medicine. He previously headed the Division of Intensive Care Medicine at the Washington D.C. Veterans Affairs Medical Center, and currently serves as a clinical professor of medicine at the University of California, San Diego Medical Center. With a focus on critical care and nephrology, Dr. Chawla has led and supported several grants and research projects centered on acute kidney injury, renal disease, extracorporeal therapies, shock, and sepsis.

2013 – Alpha Omega Alpha, George Washington University

Dr. Chawla received a bachelor’s degree from Boston University and a medical degree from The University of Medicine and Dentistry of New Jersey.

Dr. Stuart Goldstein, M.D.

Dr. Goldstein contributes expertise in nephrology and brings to the board a unique perspective from his background in pediatric care. In addition to his current role at Cincinnati Children’s Hospital Medical Center, he holds a faculty position as a professor of pediatrics for the University of Cincinnati School of Medicine. Dr. Goldstein has also led and contributed research support for several research investigations focused on device therapies, including those with emphasis on renal failure and end-stage renal disease, for various institutions.

2018 – Received the Team Research Award for Learning Networks, Cincinnati Children’s Hospital Medical Center

2017 – Elected Fellow of the American Society of Nephrology

2016 – Awarded the Presidential Citation, Society for Critical Care Medicine

Dr. Goldstein received a bachelor’s degree from Pitzer College and a medical degree from Columbia University.